Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.1900
0.00 (0.00%)
Apr 23, 2026, 3:35 PM EST

Northwest Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
316358364822830663
Market Cap Growth
17.10%-1.53%-55.72%-1.00%25.14%-47.13%
Enterprise Value
390444435881865686
Last Close Price
0.190.230.270.700.780.70
PE Ratio
-----3.70
PS Ratio
229.27260.08263.35425.38493.23660.04
PB Ratio
-6.64-7.53-4.61-17.47-7.90-5.35
EV/Sales Ratio
283.33322.41314.92455.93513.96682.10
Debt / Equity Ratio
-1.36-1.36-0.85-0.97-0.25-0.31
Net Debt / Equity Ratio
-1.30-1.30-0.83-0.92-0.18-0.18
Net Debt / EBITDA Ratio
-1.07-1.07-1.01-0.80-0.29-0.43
Net Debt / FCF Ratio
-1.33-1.33-1.12-0.76-0.35-0.51
Asset Turnover
0.030.030.050.070.050.03
Quick Ratio
0.030.030.030.050.060.11
Current Ratio
0.060.060.060.090.080.13
Return on Assets (ROA)
-69.33%-69.33%-152.28%-117.23%-117.48%-90.17%
Return on Capital Employed (ROCE)
575.50%575.50%160.10%320.10%71.00%56.30%
Earnings Yield
-18.63%-16.79%-23.02%-7.62%-12.65%27.00%
FCF Yield
-14.64%-12.91%-15.95%-6.94%-6.71%-6.68%
Buyback Yield / Dilution
-17.26%-17.26%-10.99%-10.17%-0.79%-38.99%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.